argenx to Acquire Forte Biosciences, Expanding Its Immunology Pipeline
argenx entered a definitive agreement to acquire Forte Biosciences for $77 per share in cash, adding FB102, a first-in-class anti-CD122 antibody, to its pipeline. FB102 has been studied in Phase 1b trials in vitiligo and celiac disease.
The transaction builds on argenx's earlier strategic investment in Forte.
